Subtopic Deep Dive

← Natural product bioactivities and synthesis

Triterpenoid Anticancer Mechanisms
Research Guide

What is Triterpenoid Anticancer Mechanisms?

Triterpenoid anticancer mechanisms describe the molecular pathways by which triterpenoids from natural sources induce apoptosis, inhibit proliferation, and disrupt signaling cascades like NF-κB and Akt/mTOR in cancer cells.

This subtopic covers structure-activity relationships and preclinical efficacy of triterpenoids such as celastrol, pristimerin, and glycyrrhetinic acid across cancer models including prostate, pancreatic, and colorectal. Key papers include Wang et al. (2023, 111 citations) on celastrol and Deeb et al. (2014, 72 citations) on pristimerin. Over 500 papers explore these mechanisms since 2010.

Curated Papers

Key Challenges

Why It Matters

Triterpenoids like celastrol target NF-κB and Nrf2 pathways to overcome chemotherapy resistance in pancreatic and prostate cancers (Wang et al., 2023; Deeb et al., 2014). RTA 408 modulates Keap1-Nrf2 for broad anticancer and anti-inflammatory effects (Probst et al., 2015). These mechanisms support development of low-toxicity agents from plants like Tripterygium wilfordii and licorice, advancing oncology drug discovery.

Key Research Challenges

Pathway Specificity

Triterpenoids like pristimerin inhibit multiple pathways including Akt/NF-κB/mTOR, complicating isolation of primary anticancer targets (Deeb et al., 2014). Shetty (2011) shows 18α-glycyrrhetinic acid downregulates inflammation genes in prostate cancer, but off-target effects persist. Distinguishing direct apoptosis inducers from modulators remains difficult.

Clinical Translation Barriers

Celastrol's efficacy in preclinical models faces challenges in bioavailability and toxicity for human trials (Wang et al., 2023). RTA 408 demonstrates broad activity but requires optimization for metastasis inhibition (Probst et al., 2015). Limited phase data hinders progression from in vitro to oncology applications.

Structure-Activity Optimization

Synthetic variants like CDDO-Me inhibit AKT/NF-κB in ovarian cancer, yet correlating modifications to potency is unresolved (Gao et al., 2011). Raddeanin A shows promise but needs SAR refinement for oral squamous carcinoma (Naz et al., 2020). Predicting activity from triterpenoid scaffolds challenges rational design.

Essential Papers

Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies

Cheng Wang, Shu Guang Dai, Xingtao Zhao et al. · 2023 · Biomedicine & Pharmacotherapy · 111 citations

Celastrol is a pentacyclic triterpenoid extracted from the traditional Chinese medicine Tripterygium wilfordii Hook F., which has multiple pharmacological activities. In particular, modern pharmaco...

RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity

Brandon Probst, Treviño Isaac, McCauley Lyndsey et al. · 2015 · PLoS ONE · 95 citations

Semi-synthetic triterpenoids are antioxidant inflammation modulator (AIM) compounds that inhibit tumor cell growth and metastasis. Compounds in the AIM class bind to Keap1 and attenuate Nrf2 degrad...

18α-glycyrrhetinic acid targets prostate cancer cells by down-regulating inflammation-related genes

Aditya Vittal Shetty · 2011 · International Journal of Oncology · 79 citations

Glycyrrhetinic acid is an active triterpenoid metabolite of glycyrrhizin abundantly present in licorice roots. Glycyrrhetinic acid exists as α and β stereo-isomeric forms. Both stereo-isomeric form...

Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2

Dorrah Deeb, Xiaohua Gao, Yong Bo Liu et al. · 2014 · International Journal of Oncology · 72 citations

Lack of effective therapeutics for pancreatic cancer at the present time underscores the dire need for safe and effective agents for the treatment of this malignancy. In the present study, we have ...

Anticancer Potential of Raddeanin A, a Natural Triterpenoid Isolated from Anemone raddeana Regel

Irum Naz, Shanaya Ramchandani, Muhammad Rashid Khan et al. · 2020 · Molecules · 59 citations

Natural compounds extracted from plants have gained immense importance in the fight against cancer cells due to their lesser toxicity and potential therapeutic effects. Raddeanin A (RA), an oleanan...

Paraptosis and NF-κB activation are associated with protopanaxadiol-induced cancer chemoprevention

Chong‐Zhi Wang, Binghui Li, Xiaodong Wen et al. · 2013 · BMC Complementary and Alternative Medicine · 49 citations

Exploring the Cytotoxic Effects of the Extracts and Bioactive Triterpenoids from <i>Dillenia indica</i> against Oral Squamous Cell Carcinoma: A Scientific Interpretation and Validation of Indigenous Knowledge

Maniyamma Aswathy, Kishore Banik, Parama Dey et al. · 2021 · ACS Pharmacology & Translational Science · 38 citations

Triterpenoids are ubiquitously distributed secondary metabolites, primarily scrutinized as a source of medication and preventive measures for various chronic diseases. The ease of isolation and exc...

Reading Guide

Foundational Papers

Start with Shetty (2011) for glycyrrhetinic acid's inflammation downregulation in prostate cancer and Deeb et al. (2014) for pristimerin apoptosis via Akt/NF-κB in pancreatic models, establishing core pathways.

Recent Advances

Wang et al. (2023) reviews celastrol challenges; Naz et al. (2020) details raddeanin A cytotoxicity.

Core Methods

Cell viability (MTT), apoptosis detection (annexin V, cytochrome c), signaling inhibition (Western blot for NF-κB, Akt, mTOR phosphorylation).

How PapersFlow Helps You Research Triterpenoid Anticancer Mechanisms

Discover & Search

Research Agent uses searchPapers and exaSearch to find 100+ papers on 'celastrol NF-κB cancer', then citationGraph on Wang et al. (2023) reveals 111 citing works and backward links to Deeb et al. (2014). findSimilarPapers expands to pristimerin mechanisms from Probst et al. (2015).

Analyze & Verify

Analysis Agent applies readPaperContent to extract NF-κB inhibition data from Wang et al. (2023), verifies claims with CoVe against Shetty (2011), and runs PythonAnalysis on dose-response curves from Deeb et al. (2014) for IC50 statistics. GRADE grading scores evidence strength for apoptosis pathways.

Synthesize & Write

Synthesis Agent detects gaps in NF-κB modulation between celastrol and RTA 408, flags contradictions in paraptosis claims (Wang et al., 2013). Writing Agent uses latexEditText for mechanism diagrams, latexSyncCitations with 10 papers, and latexCompile for reports; exportMermaid visualizes signaling cascades.

Use Cases

"Extract dose-response data from triterpenoid apoptosis papers and plot IC50 curves"

Research Agent → searchPapers('triterpenoid IC50 cancer') → Analysis Agent → readPaperContent(Deeb 2014) + runPythonAnalysis(pandas plot IC50 from Probst 2015, Naz 2020) → matplotlib graph of efficacy across cancers.

"Draft LaTeX review on pristimerin NF-κB mechanisms with figures"

Synthesis Agent → gap detection(pristimerin papers) → Writing Agent → latexGenerateFigure(NF-κB pathway) → latexEditText(section on Deeb 2014, Yousef 2015) → latexSyncCitations → latexCompile → PDF with 5 figures.

"Find GitHub code for triterpenoid molecular dynamics simulations"

Research Agent → searchPapers('triterpenoid MD simulation cancer') → paperExtractUrls(Cheng 2017) → paperFindGithubRepo → githubRepoInspect → Python scripts for NF-κB docking from Dillenia indica models (Aswathy 2021).

Automated Workflows

Deep Research workflow scans 50+ triterpenoid papers via searchPapers → citationGraph → structured report on NF-κB/Akt mechanisms (Wang 2023, Deeb 2014). DeepScan applies 7-step CoVe to verify celastrol claims against Shetty (2011). Theorizer generates hypotheses on RTA 408-Nrf2 for pancreatic resistance (Probst 2015).

Try Doxa for Triterpenoid Anticancer Mechanisms Research

Frequently Asked Questions

What defines triterpenoid anticancer mechanisms?

Molecular pathways where triterpenoids like celastrol and pristimerin induce apoptosis via NF-κB inhibition and mitochondrial cytochrome c release (Wang et al., 2023; Deeb et al., 2014).

What are key methods in this subtopic?

In vitro assays measure apoptosis in cancer cell lines via MTT, flow cytometry for cytochrome c, and Western blots for NF-κB/Akt phosphorylation (Shetty 2011; Huang 2011).

What are foundational papers?

Shetty (2011, 79 citations) on glycyrrhetinic acid in prostate cancer; Deeb et al. (2014, 72 citations) on pristimerin in pancreatic cells.

What open problems exist?

Improving bioavailability of celastrol for clinics and resolving multi-pathway effects for targeted therapies (Wang et al., 2023; Probst et al., 2015).